JP7456643B2 - 核酸分子の製造方法、生体用材料、および生体用材料の製造方法 - Google Patents

核酸分子の製造方法、生体用材料、および生体用材料の製造方法 Download PDF

Info

Publication number
JP7456643B2
JP7456643B2 JP2021553692A JP2021553692A JP7456643B2 JP 7456643 B2 JP7456643 B2 JP 7456643B2 JP 2021553692 A JP2021553692 A JP 2021553692A JP 2021553692 A JP2021553692 A JP 2021553692A JP 7456643 B2 JP7456643 B2 JP 7456643B2
Authority
JP
Japan
Prior art keywords
nucleic acid
vegf
acid molecule
binding
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021553692A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021085554A1 (cg-RX-API-DMAC7.html
JPWO2021085554A5 (cg-RX-API-DMAC7.html
Inventor
智子 藤田
巌 和賀
克紀 堀井
信太郎 加藤
マーティン スタントン
アンドリュー ダルビー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEC Solution Innovators Ltd
Original Assignee
NEC Solution Innovators Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEC Solution Innovators Ltd filed Critical NEC Solution Innovators Ltd
Publication of JPWO2021085554A1 publication Critical patent/JPWO2021085554A1/ja
Publication of JPWO2021085554A5 publication Critical patent/JPWO2021085554A5/ja
Application granted granted Critical
Publication of JP7456643B2 publication Critical patent/JP7456643B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2021553692A 2019-10-30 2020-10-29 核酸分子の製造方法、生体用材料、および生体用材料の製造方法 Active JP7456643B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16/668,717 2019-10-30
US16/668,717 US11613748B2 (en) 2019-10-30 2019-10-30 Method for producing nucleic acid molecule, biomaterial, and method for producing biomaterial
JPPCT/JP2020/018142 2020-04-28
PCT/JP2020/018142 WO2021084782A1 (en) 2019-10-30 2020-04-28 Method for producing nucleic acid molecule, biomaterial, and method for producing biomaterial
PCT/JP2020/040687 WO2021085554A1 (ja) 2019-10-30 2020-10-29 核酸分子の製造方法、生体用材料、および生体用材料の製造方法

Publications (3)

Publication Number Publication Date
JPWO2021085554A1 JPWO2021085554A1 (cg-RX-API-DMAC7.html) 2021-05-06
JPWO2021085554A5 JPWO2021085554A5 (cg-RX-API-DMAC7.html) 2022-07-07
JP7456643B2 true JP7456643B2 (ja) 2024-03-27

Family

ID=75688434

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021553692A Active JP7456643B2 (ja) 2019-10-30 2020-10-29 核酸分子の製造方法、生体用材料、および生体用材料の製造方法

Country Status (3)

Country Link
US (2) US11613748B2 (cg-RX-API-DMAC7.html)
JP (1) JP7456643B2 (cg-RX-API-DMAC7.html)
WO (2) WO2021084782A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026015902A1 (en) * 2024-07-12 2026-01-15 The Regents Of The University Of California Synthetic matrix for stem cell encapsulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014128289A1 (en) 2013-02-22 2014-08-28 Lumetti, Simone Biomedical device implantable in bone and/or cartilaginous tissue, and corresponding method to manufacture said biomedical device

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014128289A1 (en) 2013-02-22 2014-08-28 Lumetti, Simone Biomedical device implantable in bone and/or cartilaginous tissue, and corresponding method to manufacture said biomedical device

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biomaterials,2017年07月10日,vol. 142,pp. 52-61
森下裕貴,2016年度実績報告書 機能性材料の開発を加速させる新規RNAアプタマー修飾医用材料の創出(研究課題/領域番号 15J10771),KAKENHI-PROJECT [online],2018年01月16日,retrieved 2020/12/23, KAKEN, which retrieved from the internet,<URL: https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-15J10771/15J107712016jisseki/>
森下裕貴他,血管内皮細胞増殖因子を特異的に補足するRNAアプタマー修飾材料の機能評価,第39回日本バイオマテリアル学会大会予稿集,2017年11月13日,vol. 39,p. 157 (1P-103-I)

Also Published As

Publication number Publication date
JPWO2021085554A1 (cg-RX-API-DMAC7.html) 2021-05-06
US20220396792A1 (en) 2022-12-15
WO2021085554A1 (ja) 2021-05-06
WO2021084782A1 (en) 2021-05-06
US12595480B2 (en) 2026-04-07
US11613748B2 (en) 2023-03-28
US20210130820A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
Sakiyama-Elbert et al. Development of growth factor fusion proteins for cell‐triggered drug delivery
US6180348B1 (en) Method of isolating target specific oligonucleotide ligands
KR101399677B1 (ko) Pdgf의 제어 방출을 위한 피브린 젤 및 그의 용도
Zustiak et al. Influence of cell-adhesive peptide ligands on poly (ethylene glycol) hydrogel physical, mechanical and transport properties
RU2624036C2 (ru) Структуры слитого белка шелка пауков для связывания с органической мишенью
Robinson et al. Differential effects of substrate modulus on human vascular endothelial, smooth muscle, and fibroblastic cells
Nakaji-Hirabayashi et al. Hyaluronic acid hydrogel loaded with genetically-engineered brain-derived neurotrophic factor as a neural cell carrier
CA2572446A1 (en) Combinatorial selection of phosphorothioate aptamers for tgf-beta
WO1998043686A1 (en) Enzyme-mediated modification of fibrin for tissue engineering
JP6412866B2 (ja) 有機ターゲットに結合するための反復断片を持たないクモ糸融合タンパク質の構造
TW201706411A (zh) 結合於血管內皮生長因子受體之核酸適體
US12595480B2 (en) Method for producing nucleic acid molecule, biomaterial, and method for producing biomaterial
TW201309720A (zh) 胜肽庫
KR101667149B1 (ko) 표적 단백질 또는 표적 펩타이드 검출용 미세 유동 장치, 이의 제조방법 및 이를 이용한 표적 단백질 또는 표적 펩타이드 검출 방법
CA3125556A1 (en) Methods of producing high diversity peptide libraries and promoting protein folding
Abe et al. Structure and function of engineered stromal cell-derived factor-1α
EP1668133A1 (en) Coiled-coil fusion proteins comprising cell receptor domains
Parvez Aptamers for Alginate Hydrogels and Diabetic Wound Healing
JP7405400B2 (ja) 核酸分子およびその用途
WO2025058014A1 (ja) 核酸アプタマー及び当該核酸アプタマーを含む骨再生誘導材
Bahri et al. A multifunctional fusion peptide for tethering to hydroxyapatite and selective capture of bone morphogenetic protein from extracellular milieu
KR20210134990A (ko) 재조합 GpIbα 수용체 단백질을 포함하는 조성물
JP6963221B2 (ja) 核酸分子およびその用途
KR20180089144A (ko) 피브로넥틴 edb을 골격으로 한 비항체 단백질 스캐폴드 라이브러리 및 그의 용도
CN120283055A (zh) 异多聚体蛋白质的制造方法、蛋白质、核酸、表达载体、转化体、以及蛋白质的制造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220421

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240307

R150 Certificate of patent or registration of utility model

Ref document number: 7456643

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150